Introduction
============

Capsaicin, the pungent extract of red pepper (capsicum), has gained widespread use as a research tool among clinical investigators, as it induces cough in humans in a safe \[[@B1]\], dose-dependent, and reproducible manner \[[@B2],[@B3]\]. Capsaicin cough challenge in humans was first described in 1984 \[[@B4]\], and has since been used to evaluate the effect of numerous pharmacological agents on cough reflex sensitivity. Although many drugs have been shown to inhibit induced cough in the laboratory, others have failed to do so, including agents widely regarded as clinically effective antitussives.

Methods
=======

A United States National Library of Medicine (PubMed) search was performed in September, 2012 using the search terms "cough" and "capsaicin" limited to human studies published in English. The abstracts of the 328 articles meeting those search criteria were reviewed and 56 studies were identified in which capsaicin cough challenge was employed to assess the effect of a pharmacological intervention on cough reflex sensitivity. Studies in which a positive drug effect was demonstrated (n = 33) are listed in Table  [1](#T1){ref-type="table"}\[[@B5]-[@B37]\]; trials in which no effect was noted (n = 30) are summarized in Table  [2](#T2){ref-type="table"}\[[@B4],[@B10],[@B12],[@B17]-[@B19],[@B35],[@B37]-[@B59]\]. In seven of these studies, multiple drugs and/or multiple subject groups were evaluated, resulting in both positive and negative results in terms of assessment of drug activity. As the purpose of this review was to assess drug trials in which a potential therapeutic (antitussive) effect of a drug was being evaluated, studies demonstrating enhancement of cough reflex sensitivity by angiotensin-converting enzyme (ACE) inhibitors or other agents were excluded.

###### 

Drugs shown to inhibit cough reflex sensitivity to capsaicin

  **1**^**st**^**author**   **Ref. \#**   **Year**   **Drug**              **Subject population**
  ------------------------- ------------- ---------- --------------------- ----------------------------
  Wise P                    \[[@B5]\]     2012       menthol               healthy volunteers
  Takemura M                \[[@B6]\]     2012       montelukast           cough-variant asthma
  Ekstrand Y                \[[@B7]\]     2011       inhaled steroids      asthma
  Ishiura Y                 \[[@B8]\]     2010       etodolac              sinobronchial syndrome
  Ishiura Y                 \[[@B9]\]     2009       etodolac              asthma
  Dicpinigaitis P           \[[@B10]\]    2009       guaifenesin           viral URI
  Davenport P               \[[@B11]\]    2009       nicotine              healthy smokers
  Dicpinigaitis P           \[[@B12]\]    2008       tiotropium            viral URI
  Ishiura Y                 \[[@B13]\]    2008       suplatast             atopic cough
  Ferrari M                 \[[@B14]\]    2007       omeprazole            asthma + GERD
  Usmani O                  \[[@B15]\]    2005       theobromine           healthy volunteers
  Shioya T                  \[[@B16]\]    2004       epinastine            atopic cough
  Dicpinigaitis P           \[[@B17]\]    2003       guaifenesin           viral URI
  Ishiura Y                 \[[@B18]\]    2003       carbocysteine         asthma
  Ishiura Y                 \[[@B19]\]    2003       seratrodast           chronic bronchitis
  Shioya T                  \[[@B20]\]    2002       suplatast             cough-variant asthma
  Dicpinigaitis P           \[[@B21]\]    2002       zafirlukast           cough-variant asthma
  Ceyhan B                  \[[@B22]\]    2002       oxolamine             COPD
  Dicpinigaitis P           \[[@B23]\]    2000       baclofen              cervical SCI
  Brightling C              \[[@B24]\]    2000       budesonide            eosinophilic bronchitis
  Dicpinigaitis P           \[[@B25]\]    1998       baclofen              healthy volunteers
  Shioya T                  \[[@B26]\]    1998       azelastine            asthma
  Dicpinigaitis P           \[[@B27]\]    1997       baclofen              healthy volunteers
  Shioya T                  \[[@B28]\]    1996       azelastine            cough-variant asthma
  Fujimura M                \[[@B29]\]    1995       indomethacin          asthma, chronic bronchitis
  Hargreaves M              \[[@B30]\]    1995       sodium cromoglycate   ACE-inhibitor cough
  Hansson L                 \[[@B31]\]    1994       lignocaine            healthy volunteers
  Van Wyck M                \[[@B32]\]    1994       glycopyrrolate        ACE-inhibitor cough
  Cazzola M                 \[[@B33]\]    1993       theophylline          ACE-inhibitor cough
  Foster G                  \[[@B34]\]    1991       sulindac              healthy volunteers
  McEwan J                  \[[@B35]\]    1990       sulindac              ACE-inhibitor cough
  Choudry N                 \[[@B36]\]    1990       lignocaine            healthy volunteers
  Fuller R                  \[[@B37]\]    1988       codeine,morphine      healthy volunteers

Abbreviations: *URI*-acute upper respiratory tract infection; *GERD*-gastroesophageal reflux disease; *SCI*-spinal cord injury; *ACE*-angiotensin-converting enzyme.

###### 

Drugs shown not to inhibit cough reflex sensitivity to capsaicin

  **1**^**st**^**author**   **Ref. \#**   **Year**   **Drug**                    **Subject population**
  ------------------------- ------------- ---------- --------------------------- ----------------------------
  Ryan M                    \[[@B38]\]    2012       gabapentin                  chronic cough
  Yousaf N                  \[[@B39]\]    2010       erythromycin                chronic cough
  Dicpinigaitis P           \[[@B10]\]    2009       benzonatate                 viral URI
  Dicpinigaitis P           \[[@B12]\]    2008       tiotropium                  healthy volunteers
  Davenport P               \[[@B40]\]    2007       codeine                     healthy volunteers
  Dicpinigaitis P           \[[@B41]\]    2003       fexofenadine                healthy volunteers
  Dicpinigaitis P           \[[@B17]\]    2003       guaifenesin                 healthy volunteers
  Ishiura Y                 \[[@B18]\]    2003       ambroxol                    asthma
  Ishiura Y                 \[[@B19]\]    2003       pranlukast                  chronic bronchitis
  Dicpinigaitis P           \[[@B42]\]    2001       celecoxib                   asthma
  Fujimura M                \[[@B43]\]    2000       mexiletine                  healthy volunteers
  Dicpinigaitis P           \[[@B44]\]    1999       zafirlukast                 asthma without cough
  Capon D                   \[[@B45]\]    1996       dextromethorphan            healthy volunteers
  Hansson L                 \[[@B46]\]    1994       nicotine                    healthy nonsmokers
  Hutchings H               \[[@B47]\]    1994       codeine                     healthy volunteers
  O'Connell F               \[[@B48]\]    1994       clonidine                   healthy volunteers
  Fujimura M                \[[@B49]\]    1993       procaterol                  asthma, chronic bronchitis
  Choudry N                 \[[@B50]\]    1993       MAO inhibitors              healthy volunteers
  Stone R                   \[[@B51]\]    1993       5-HT (serotonin)            healthy volunteers
  Fujimura M                \[[@B52]\]    1992       procaterol                  healthy volunteers
  Ventresca P               \[[@B53]\]    1992       furosemide                  healthy volunteers
  Karlsson J                \[[@B54]\]    1992       furosemide, HCTZ            healthy volunteers
  Studham J                 \[[@B55]\]    1992       terfenadine                 healthy volunteers
  Choudry N                 \[[@B56]\]    1991       inhaled mu opioid agonist   healthy volunteers
  Smith C                   \[[@B57]\]    1991       salbutamol, ipratropium     healthy volunteers
  Choudry N                 \[[@B58]\]    1991       granisteron (5-HT3)         healthy volunteers
  McEwan J                  \[[@B35]\]    1990       sulindac                    idiopathic cough
  Hansson L                 \[[@B59]\]    1988       nedocromil                  healthy volunteers
  Fuller R                  \[[@B37]\]    1988       inhaled opiates             healthy volunteers
  Collier J                 \[[@B4]\]     1984       sodium cromoglycate         healthy volunteers

Abbreviations: *URI*-acute upper respiratory tract infection; *MAO*-monoamine oxidase; *HCTZ*-hydrochlorothiazide.

Discussion
==========

This review has identified 33 studies in which a pharmacological intervention was demonstrated to inhibit cough reflex sensitivity to inhaled capsaicin in a variety of subject populations, thus supporting the role of cough challenge as a useful clinical tool in the evaluation of potential antitussives \[[@B3]\]. A striking difference between the studies showing a positive drug effect (Table  [1](#T1){ref-type="table"}), and those failing to demonstrate a change in cough reflex sensitivity (Table  [2](#T2){ref-type="table"}) is the predominant subject populations studied. Of the negative studies, 70% involved evaluation of healthy volunteers. Among the trials displaying a positive drug effect, only 27% evaluated healthy volunteers, while the majority (73%) investigated various forms of pathological cough. Of note, multiple agents were shown to inhibit cough reflex sensitivity in pathological cough, while having no effect in healthy volunteers, including guaifenesin \[[@B10],[@B17]\] and tiotropium \[[@B12]\] in cough due to acute viral upper respiratory tract infection (URI; common cold). The leukotriene receptor antagonist zafirlukast inhibited capsaicin-induced cough in subjects with cough-variant asthma \[[@B21]\], but not in stable asthmatics without cough and healthy volunteers \[[@B44]\]. Interestingly, gabapentin has recently been shown to improve cough-specific quality of life in patients with refractory chronic cough, without affecting cough reflex sensitivity \[[@B38]\]. This particular study highlights the concept that the optimal approach to the evaluation of a potential antitussive agent should be multifaceted, with cough reflex sensitivity measurement complementing other measures, such as objective cough counting and subjective symptom-based questionnaires.

Conspicuous in their absence from the list of agents having demonstrated the ability to inhibit cough reflex sensitivity to capsaicin during URI are codeine and dextromethorphan, two of the most commonly used agents worldwide for the treatment of cough due to the common cold \[[@B60]\]. The only agents demonstrating the ability to inhibit cough reflex sensitivity to capsaicin in healthy volunteers were theobromine \[[@B15]\], baclofen \[[@B25],[@B27]\], inhaled lignocaine \[[@B31],[@B36]\], sulindac \[[@B34]\], systemic opiates \[[@B37]\], menthol \[[@B5]\] and, in healthy smokers, nicotine \[[@B11]\]. Interestingly, this list includes drugs thought to be centrally acting antitussives, as well as agents whose cough-inhibiting properties are presumed to occur through a peripheral mechanism.

Limiting the evaluation of a potential modulator of cough reflex sensitivity to a study group of healthy volunteers, whose cough reflex is not hyperresponsive, may not allow the drug to demonstrate its inhibitory effect. Thus, subjects with pathological cough appear to comprise the optimal study population when evaluating the effects of a potential antitussive agent on cough reflex sensitivity. The particular type of pathological cough best suited for evaluation of a novel antitussive may depend on the specific pharmacological action of the drug, and currently remains a question under vigorous debate.
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